Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer PatientsReport as inadecuate




Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients - Download this document for free, or read online. Document in PDF available to download.

BioMed Research InternationalVolume 2014 2014, Article ID 203601, 13 pages

Review Article

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands

Radboud Translational Medicine B.V., Reinier Postlaan 2, 6525 GC, Nijmegen, The Netherlands

Roche Pharma Research & Early Development, Large Molecule Research, Nonnenwald 2, 82377 Penzberg, Germany

Received 14 March 2014; Accepted 23 April 2014; Published 28 May 2014

Academic Editor: Roland Haubner

Copyright © 2014 Floor C. J. van de Watering et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Antibody based positron emission tomography immuno-PET imaging is of increasing importance to visualize and characterize tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy outcome. In recent years the field is focused on

Zr, a radiometal with near ideal physical and chemical properties for immuno-PET. In this review we will discuss the production of  

Zr, the bioconjugation strategies, and applications in pre-clinical studies of  

Zr-based immuno-PET in oncology. To date,

Zr-based PET imaging has been investigated in a wide variety of cancer-related targets. Moreover, clinical studies have shown the feasibility for

Zr-based immuno-PET to predict and monitor treatment, which could be used to tailor treatment for the individual patient. Further research should be directed towards the development of standardized and robust conjugation methods and improved chelators to minimize the amount of released Zr

from the antibodies. Additionally, further validation of the imaging method is required. The ongoing development of new

Zr-labeled antibodies directed against novel tumor targets is expected to expand applications of  

Zr-labeled immuno-PET to a valuable method in the medical imaging.





Author: Floor C. J. van de Watering, Mark Rijpkema, Lars Perk, Ulrich Brinkmann, Wim J. G. Oyen, and Otto C. Boerman

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents